Thomas Riley

Learn More
3-Phenyloctahydropyrido[2,1-c][1,4]oxazine hydrochloride and the 10R and 10S diastereomers have been synthesized from (+/-)-, (+)-, and (-)-2-piperidinemethanol. Treatment of 2-piperidinemethanol with alpha-bromoacetophenone gave 3-hydroxy-3-phenyloctahydropyrido[2,1-c][1,4]oxazine which was readily converted to the 3-phenyl derivative by catalytic(More)
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major cause of nosocomial infection in Australia. In Western Australia, a new type of MRSA (WA MRSA) appeared some years ago and has become endemic in the community. While initially susceptible to most antibiotics, WA MRSA has begun to acquire additional resistance determinants, including(More)
A number of 2-(arylamino)-4(3H)-quinazolinones (2a-i) that possess several of the pharmacophore moieties necessary for binding to the inhibitor site of the enzyme aldose reductase were synthesized and tested for their ability to inhibit crude aldose reductase obtained from rat lens. Only those quinazolinones that possess an acidic moiety on the(More)
A method for the prediction of the retention index of drugs on C18 reversed-phase columns was developed and then applied to a series of drugs that were structurally related to morphine and to a series related to fentanyl. The HPLC retention index (/) of the test compounds was estimated using the equation: / = 200 pi + /ref. where pi was the sum of the(More)
A series of substituted 3-aryl- and hydroxy-3-aryloctahydropyrido[2,1-c][1,4]oxazines has been synthesized for purposes of investigating potentially useful CNS pharmacological actions of this novel heterocyclic system. The preferred conformation of the bicyclic system of the parent compounds, 1 and 2, has been shown to be trans with equatorial orientation(More)
The existence of several forms of cAMP phosphodiesterase having differing kinetic characteristics suggests the feasibility of developing tissue-selective inhibitors of this enzyme. This observation is of particular importance in the development of therapeutic agents for the management of reversible obstructive airways disorders. The present report describes(More)